Kaleido Biosciences has closed a $101m series C funding round that involved the Abu Dhabi Investment Authority, investment firm Fidelity Management and venture capital company Rock Springs Capital.

The business is a clinical-stage healthcare company that focuses on microbiome research. It has raised a total of $166m in funding to date.